Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04705454 No longer available - Clinical trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start date: n/a
Phase:
Study type: Expanded Access

The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials. ADC Therapeutics will evaluate patients for approval into the program.

NCT ID: NCT04667234 No longer available - Clinical trials for Non Small-cell Lung Cancer

Expanded Access of Sotorasib

Start date: n/a
Phase:
Study type: Expanded Access

The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.

NCT ID: NCT04636554 No longer available - Covid19 Clinical Trials

Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia

Start date: n/a
Phase:
Study type: Expanded Access

Phage Treatment in Covid-19 Patients with Bacterial Co-Infections

NCT ID: NCT04559555 No longer available - Clinical trials for Acute Lymphoblastic Leukemia (ALL)

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this Cohort Treatment Plan is to allow access to nilotinib for eligible patients diagnosed with relapsed or refractory Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

NCT ID: NCT04381091 No longer available - Clinical trials for Leber's Hereditary Optic Neuropathy

Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study

US EAP LHON
Start date: n/a
Phase:
Study type: Expanded Access

Expanded Access Program for Idebenone in Patients with Leber's Hereditary Optic Neuropathy who completed the LEROS Study

NCT ID: NCT04360486 No longer available - Clinical trials for Severe Acute Respiratory Syndrome Coronavirus 2

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

Start date: n/a
Phase:
Study type: Expanded Access

This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.

NCT ID: NCT04355494 No longer available - COVID-19 Clinical Trials

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This protocol provides access to eculizumab treatment for participants with severe COVID-19.

NCT ID: NCT04313075 No longer available - Clinical trials for Metastatic Triple-Negative Breast Carcinoma

A Compassionate Use Study of Leronlimab in Breast Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.

NCT ID: NCT04173013 No longer available - Clinical trials for Urinary Tract Infections

Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)

Start date: n/a
Phase:
Study type: Expanded Access

An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance.

NCT ID: NCT03925649 No longer available - Clinical trials for Spinal Cord Injury at C5-C7 Level

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI

Start date: n/a
Phase:
Study type: Expanded Access

This study is expanded access to an Investigational New Drug (IND) for an individual patient with spinal cord injury (SCI) at cervical spine 5-6 (C 5-6) designed to provide access to autologous adipose-derived mesenchymal stem cells (HB-adMSCs)